A Phase 1 interventional study of TP-05 (lotilaner oral capsules) and Placebo in Healthy, sponsored by Tarsus Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-03.
Sponsored by Tarsus Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 1, Randomized, Double-Blind, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Food-Effect and Pharmacokinetics of TP-05 in Healthy Subjects
This Phase 1 study is a randomized, double-blind, single- and multiple-ascending dose trial to evaluate the safety, tolerability, food-effect, and pharmacokinetics of TP-05 in healthy subjects. Subjects will be enrolled in 5 sequential, ascending single dose cohorts and 3 multiple, ascending dose cohorts. Dose escalation will be approved by a safety monitoring committee before beginning the next cohort. The Safety Review Committee (SRC) will evaluate if any dose-limiting adverse events (AEs) through Day 15 (in Cohorts 1-5) or through Day 36 (in Cohorts 6-8) occurred in a cohort before proceeding to dosing in the next dose level. In addition, the SRC will review selected PK parameters after selected cohorts. Skin punch biopsies, and venous, capillary, and urine samples may be collected at various timepoints for pharmacokinetic analysis. Safety assessments include monitoring of adverse events, clinical laboratory testing, vital sign measurements, physical examinations, and ECGs. A blood sample may also be collected to evaluate tick mortality upon exposure.
Tarsus Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of TP-05 (lotilaner oral capsules) at 4 dose levels in ascending order
Drug: TP-05 (lotilaner oral capsules)
Single dose of Placebo
Drug: Placebo
Four doses of TP-05 (lotilaner oral capsules) at 3 dose levels in ascending order
Drug: TP-05 (lotilaner oral capsules)
Four doses of Placebo
Drug: Placebo
Single dose of TP-05 (lotilaner oral capsules) in a fasted state
Drug: TP-05 (lotilaner oral capsules)
Single dose of placebo in a fasted state
Drug: Placebo
TP-05 (lotilaner oral capsules)
Placebo to match TP-05 (lotilaner oral capsules)
Incidence of treatment emergent adverse events (TEAEs)
Evaluate the safety of TP-05 through the incidence rate of TEAEs
Time frame: up to 151 days
Clinically significant changes from Baseline chemistry laboratory tests
Evaluate the safety of TP-05 through clinically significant changes from Baseline chemistry laboratory tests
Time frame: up to 151 days
Clinically significant changes from Baseline hematology laboratory tests
Evaluate the safety of TP-05 through clinically significant changes from Baseline hematology laboratory tests
Time frame: up to 151 days
Clinically significant changes from Baseline general appearance
Evaluate the safety of TP-05 through clinically significant changes from Baseline general appearance
Time frame: up to 151 days
Clinically significant changes from Baseline physical examination of head, ears, nose, and throat
Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of head, ears, nose, and throat
Time frame: up to 151 days
Clinically significant changes from Baseline physical examination of neck (thyroid)
Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of neck (thyroid)
Time frame: up to 151 days
Clinically significant changes from Baseline physical examination of respiratory system
Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of respiratory system
Time frame: up to 151 days
Clinically significant changes from Baseline physical examination of cardiovascular system
Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of cardiovascular system
Time frame: up to 151 days
Clinically significant changes from Baseline physical examination of gastrointestinal system
Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of gastrointestinal system
Time frame: up to 151 days
Clinically significant changes from Baseline physical examination of neurological system
Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations of neurological system
Time frame: up to 151 days
Clinically significant changes from Baseline physical examination of musculoskeletal system (extremities)
Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examination of musculoskeletal system (extremities)
Time frame: up to 151 days
Clinically significant changes from Baseline physical examination of skin
Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examination of skin
Time frame: up to 151 days
Clinically significant changes from Baseline vital signs
Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs (including temperature \[degrees Celsius\], pulse rate \[beats per minute\], respiration rate \[breaths per minute\], and changes in systolic and diastolic blood pressure \[mmHg\])
Time frame: up to 151 days
Clinically significant changes from Baseline vital signs (temperature [degrees Celsius])
Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs including temperature \[degrees Celsius\]
Time frame: up to 151 days
Clinically significant changes from Baseline vital signs (pulse rate [beats per minute])
Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs including pulse rate \[beats per minute\]
Time frame: up to 151 days
Clinically significant changes from Baseline vital signs (respiration rate [breaths per minute])
Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs including respiration rate \[breaths per minute\]
Time frame: up to 151 days
Clinically significant changes from Baseline vital signs (systolic and diastolic blood pressure [mmHg])
Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs including changes in systolic and diastolic blood pressure \[mmHg\])
Time frame: up to 151 days
Clinically significant changes from Baseline electrocardiograms (ECGs)
Evaluate the safety of TP-05 through clinically significant changes from Baseline ECGs (including changes in mean ventricular rate \[beats/min\], pulse rate \[msec\], QRS duration \[msec\], QT interval \[msec\], QTcF interval \[msec\])
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include Cmax at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include Tmax at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include Tlag at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include AUC0-168 at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include AUC0-2880 at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include AUC0-t at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include AUC0-inf at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include CL/F at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include Vz/F at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include eff at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include Thalf at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include λz at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include AUC%extrap at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include MRT0-t at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include Rac at various times
Time frame: up to 151 days
Exposure and PK of lotilaner in whole blood
PK parameters for whole blood sampling methods following dose administration will be evaluated and include Ctrough at various times
Time frame: up to 151 days
Urine exposure and renal PK of lotilaner
PK parameters for urine sampling methods will be evaluated and include Ae.
Time frame: 3 days
Urine exposure and renal PK of lotilaner
PK parameters for urine sampling methods will be evaluated and include fe.
Time frame: 3 days
Urine exposure and renal PK of lotilaner
PK parameters for urine sampling methods will be evaluated and include CLr0-48.
Time frame: 3 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Cmax at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Tmax at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Tlag at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include AUC0-168 at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include AUC0-2880 at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include AUC0-t at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include AUC0-inf at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include CL/F at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Vz/F at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Thalf at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include λz at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include AUC%extrap at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include MRT0-t at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Rac at various times
Time frame: up to 151 days
Impact of fasting on the PK of lotilaner
PK parameters will be evaluated for lotilaner following dosing with food and under fasting conditions. Parameters include Ctrough at various times
Time frame: up to 151 days
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2021 to primary completion in Mar 2022, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lotilaner
Tarsus Pharmaceuticals, Inc.